Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center
Authors' conclusion
Results suggest that long-term intrathecal treatment using a multidrug regimen for cancer-related pain through cervical intrathecal catheters was suitable and safe in our study population.
Study context
- Population
- Patients with refractory cancer pain treated with cervical intrathecal drug delivery systems (IDDS), January 2010 to December 2022
- Participants
- 98 patients
- Exposure
- Post-implant vs initial pain score
- Cervical IDDSn = 98
- Outcome
- Pain (NRS) vs initial pain score
Methodological detailsmonocentric, Followed via day-hospital visits and telephone calls at least monthly
- Monocentric
- Followed via day-hospital visits and telephone calls at least monthly
Main finding
As reported in the abstract
Pain relief vs initial pain score (NRS)
- Significant pain relief vs initial pain score after 1 week, 1 month, 2 and 3 months
- p<0.01
- ≥50% reduction in initial pain level during the first week of intrathecal implant (% of cases)
- 93%
Observational data: associations, not effects.
Further findings
Presurgical maximum numeric rating scale (NRS) (mean±SD)
- Mean presurgical maximum NRS
- 8.02±0.24
Oral morphine equivalent daily dose before implant (mean) · mean presurgical
- Mean oral morphine equivalent daily dose
- 562.56±127.72 mg
Survival time after intrathecal treatment start (mean)
- Mean survival time after intrathecal treatment start
- 208.48±67 days
Original publication
Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center. Reg Anesth Pain Med. Published 16 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →